Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 non-inferiority trial of exenatide versus Byetta in type 2 diabetes
ChiCTR-IPR-15006558Phase 3Completed
- Sponsor
- Peking University Third Hospital
- Start
- Jul 2011
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of exenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: HbA1c. Started Jul 2011; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-IPR-15006558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006558.